 |
|
|
|
|
|
|
| |
|
ITT解析群 |
|
インフルエンザ陽性者群 |
|
高リスク群 |
|
|
|
|
|
|
|
| |
|
プラセボ
(％) |
実薬
(％) |
差
(95％ CI) |
|
|
プラセボ
(％) |
実薬
(％) |
差
(95％ CI) |
|
|
プラセボ
(％) |
実薬
(％) |
差
(95％ CI) |
|
|
|
|
|
|
|
|
|
|
|
64/228
(28％)
|
49/227
(22％)
|
6％
(−2％ to 15％)
p＝0.135
|
|
|
48/160
(30％) |
38/161
(24％)
|
6％
(−4％ to 17％)
p＝0.243
|
|
|
18/39
(46％) |
5/37
(14％)
|
32％
(11％ to 54％)
p＝0.004
|
|
|
|
|
|
|
|
|
|
|
|
86/365
(24％)
|
74/412
(l8％)
|
6％
(0％ to l2％)
p＝0.066 |
|
|
57/257
(22％)
|
48/312
(15％)
|
7％
(0％ to 14％)
p＝0.049 |
|
|
17/60
(28％)
|
17/49
(35％)
|
＋6％
(CI not given)
p＝0.612 |
|
|
|
|
|
|
|
|
|
|
|
61/182
(34％)
|
40/174
(23％)
|
11％
(l％ to 20％)
p＝0.037 |
|
|
47/141
(33％)
|
33/136
(24％)
|
9％
(−2％ to 20％)
p＝0.125 |
|
|
11/19
(58％)
|
4/13
(31％)
|
27％
(CI not given)
p＝0.250 |
|
|
|
|
|
|
|
|
|
|
|
211/775
(27％)
|
163/813
(20％)
|
7％
(3％ to 11％)
p＜0.001 |
|
|
152/558
(27％)
|
119/609
(20％)
|
8％
(3％ to 13％)
p＝0.002 |
|
|
46/118
(39％)
|
26/99
(26％)
|
13％
(CI−1％ to 26％)
p＝0.065 |
|
|
|
|
|
|
|
|